| Literature DB >> 28968560 |
Anna M Gram1, Chenglong Sun2, Sanne L Landman3, Timo Oosenbrug4, Hester J Koppejan5, Mark J Kwakkenbos6, Rob C Hoeben7, Søren R Paludan8, Maaike E Ressing9.
Abstract
Most cells are believed to be capable of producing type I interferons (IFN I) as part of an innate immune response against, for instance, viral infections. In macrophages, IFN I is potently induced upon cytoplasmic exposure to foreign nucleic acids. Infection of these cells with herpesviruses leads to triggering of the DNA sensors interferon-inducible protein 16 (IFI16) and cyclic GMP-AMP (cGAMP) synthase (cGAS). Thereby, the stimulator of interferon genes (STING) and the downstream molecules TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3) are sequentially activated culminating in IFN I secretion. Human gamma-herpesviruses, such as Epstein-Barr virus (EBV), exploit B cells as a reservoir for persistent infection. In this study, we investigated whether human B cells, similar to macrophages, engage the cytoplasmic DNA sensing pathway to induce an innate immune response. We found that the B cells fail to secrete IFN I upon cytoplasmic DNA exposure, although they express the DNA sensors cGAS and IFI16 and the signaling components TBK1 and IRF3. In primary human B lymphocytes and EBV-negative B cell lines, this deficiency is explained by a lack of detectable levels of the central adaptor protein STING. In contrast, EBV-transformed B cell lines did express STING, yet both these lines as well as STING-reconstituted EBV-negative B cells did not produce IFN I upon dsDNA or cGAMP stimulation. Our combined data show that the cytoplasmic DNA sensing pathway is dysfunctional in human B cells. This exemplifies that certain cell types cannot induce IFN I in response to cytoplasmic DNA exposure providing a potential niche for viral persistence.Entities:
Keywords: DNA sensing; Epstein-Barr virus; Human B cells; Innate immune signaling; Type I interferons; cGAS-STING pathway
Mesh:
Substances:
Year: 2017 PMID: 28968560 DOI: 10.1016/j.molimm.2017.08.025
Source DB: PubMed Journal: Mol Immunol ISSN: 0161-5890 Impact factor: 4.407